Compare Regeneron Pharmaceuticals Inc (REGN) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Boston Beer Company Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $748.62 (market cap $76.14B), while Boston Beer Company Inc trades at $171.28 (market cap $1.76B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 43.3× Boston Beer Company Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Boston Beer Company Inc for 59 Days on average.
| REGN | SAM | |
|---|---|---|
Market Cap | $76.14B | $1.76B |
Volume | 500,239 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $260.05 |
52-Week Low | $557.73 | $161.08 |
Typical Hold Time | 107 Days | 59 Days |
Enterprise Value | $70.85B | $1.53B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Boston Beer Company (SAM) trades at $171.33, up 1.89% with a bullish technical signal despite mixed earnings performance. The stock shows strong cash flow generation with $270M operating cash flow in 2025, but faces profitability challenges with negative net income margin of -3.64%. Recent developments include new product launches and marketing initiatives targeting younger demographics, while analyst consensus remains cautious with 72% hold ratings.
SAM presents a mixed investment case with attractive valuation metrics (P/E 22.7, P/S 0.94) offset by profitability concerns. Upside potential exists from innovation initiatives and brand investments, but investors face risks from volume declines and competitive pressures. The stock trades near consensus price target of $204.44, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
